This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
I was lucky enough to be able to raise the concerns of the CLL/SLL community to the many healthcare professionals who read the Journal of the American Medical Association (JAMA) with a report where I was both quoted and have a published commentary.
Take a look at Questions Remain About Who Will Get Monoclonal Antibodies for COVID-19 Pre-Exposure Prophylaxis, and also scroll down to read the comments.
These shortages should be resolved in a matter of months, but that might be too late for some. We at CLL Society, along with other charities representing different immunocompromised communities, are pushing members of Congress, the White House, and all the other agencies involved in making decisions that impact us (NIH, CDC, FDA) for faster, wider, and more equitable distribution of these lifesaving therapies. We will keep pushing until we have the access we need.
We are so close to a solution, but we are not there yet.
Stay strong. Stay safe. We are all in this together.
Brian Koffman MDCM (retired) MS Ed (he, him, his)
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.